Description:

This advanced course provides comprehensive updates on the classification and diagnosis of myelodysplastic syndromes (MDS) according to the latest World Health Organization (WHO) 5th edition guidelines. Expert instructors will delve into the nuances of hematopathology, focusing on the haematolymphoid tumors commonly encountered in clinical practice. Part 4 of the series specifically covers MDS, including subtypes, diagnostic criteria, prognostic factors, and treatment implications.

Key Highlights:

• Updates on MDS classification
• In-depth analysis of WHO 5th edition guidelines
• Clinical implications and treatment strategies

What you will learn:

• Enhanced Understanding of MDS Classification
  Learn about the different subtypes of myelodysplastic syndromes and their diagnostic criteria.
• Application of WHO 5th Edition Guidelines
  Gain insights into the updated WHO classification system for haematolymphoid tumors.
• Clinical Relevance and Prognostic Factors
  Understand the clinical implications of MDS and the prognostic factors that impact patient outcomes.
• Treatment Strategies and Emerging Therapies
  Explore the current treatment options for MDS and emerging therapies on the horizon.